These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12161080)

  • 21. Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.
    Jung SH
    Contemp Clin Trials; 2015 May; 42():9-17. PubMed ID: 25749311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Approaches to handling data when a phase II trial deviates from the pre-specified Simon's two-stage design.
    Wu Y; Shih WJ
    Stat Med; 2008 Dec; 27(29):6190-208. PubMed ID: 18800338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal two-stage design of single arm Phase II clinical trials based on median event time test.
    Park Y
    PLoS One; 2021; 16(2):e0246448. PubMed ID: 33556130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How a new stratified adaptive phase II design could improve targeting population.
    Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
    Stat Med; 2011 Jun; 30(13):1555-62. PubMed ID: 21432892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitation.
    Berchialla P; Zohar S; Baldi I
    Pharm Stat; 2019 Mar; 18(2):198-211. PubMed ID: 30440109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Research design for patient selection in clinical trials phase II].
    Kramar A; Potvin D; Hill C
    Rev Epidemiol Sante Publique; 1996 Aug; 44(4):364-71. PubMed ID: 8927779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Sample Size Calculation using SAS for PhaseⅡin Two-stage Clinical Trials of Anti-tumor Drugs].
    Li JJ; Hou LS; Zhu P; Du XD; Zhu CR
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Jul; 48(4):600-604. PubMed ID: 28752982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-stage k-sample designs for the ordered alternative problem.
    Shan G; Hutson AD; Wilding GE
    Pharm Stat; 2012; 11(4):287-94. PubMed ID: 22408050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-stage phase II survival trial design.
    Wu J; Chen L; Wei J; Weiss H; Chauhan A
    Pharm Stat; 2020 May; 19(3):214-229. PubMed ID: 31749311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal flexible designs in phase II clinical trials.
    Chen TT; Ng TH
    Stat Med; 1998 Oct; 17(20):2301-12. PubMed ID: 9819829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Point estimation and p-values in phase II adaptive two-stage designs with a binary endpoint.
    Kunzmann K; Kieser M
    Stat Med; 2017 Mar; 36(6):971-984. PubMed ID: 28028823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal three-stage designs for phase II cancer clinical trials.
    Chen TT
    Stat Med; 1997 Dec; 16(23):2701-11. PubMed ID: 9421870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sample size and design considerations for phase II clinical trials with correlated observations.
    Sargent DJ; Sloan JA; Cha SS
    Control Clin Trials; 1999 Jun; 20(3):242-52. PubMed ID: 10357497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive designs for single-arm phase II trials in oncology.
    Englert S; Kieser M
    Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On Simon's two-stage design for single-arm phase IIA cancer clinical trials under beta-binomial distribution.
    Liu J; Lin Y; Shih WJ
    Stat Med; 2010 May; 29(10):1084-95. PubMed ID: 20077506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay.
    Mukherjee A; Wason JMS; Grayling MJ
    Eur J Cancer; 2022 May; 166():270-278. PubMed ID: 35344852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.
    Ivanova A; Paul B; Marchenko O; Song G; Patel N; Moschos SJ
    J Biopharm Stat; 2016; 26(1):141-9. PubMed ID: 26368744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.